drugset / Trial / NCT00002721

Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

NCT00002721

Phase 1 Completed 18 enrolled University of New Mexico
Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of doxorubicin plus estramustine in treating patients with metastatic recurrent prostate cancer that does not respond to hormone therapy.

Timeline

Start
1995-03
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified Intravenous
Subject estramustine Other / unclassified Oral

Indications